Blog
RSS FeedPosted by Michael Wonder on 11 Jan 2022
COUR Pharmaceuticals receives FDA fast track designation for CNP-104 for the treatment of primary biliary cholangitis
10 January 2021 - COUR Pharmaceuticals today announced the U.S. FDA granted fast track designation to the Company's investigational therapy CNP-104 ...
Posted by Michael Wonder on 07 Jan 2022
Dynacure receives fast track designation for DYN101, an investigational antisense oligonucleotide for the treatment of myotubular and centronuclear myopathies
6 January 2022 - Dynacure today announced that the U.S. FDA has granted fast track designation for its lead product ...
Posted by Michael Wonder on 04 Jan 2022
Genprex receives U.S. FDA fast track designation for Reqorsa immunogene therapy in combination with Keytruda for the treatment of non-small-cell lung cancer
3 January 2022 - Second FDA fast track designation further validates the potential of Reqorsa. ...
Posted by Michael Wonder on 03 Jan 2022
FDA grants ILiAD Biotechnologies fast track designation for next generation pertussis vaccine BPZE1
3 January 2021 - ILiAD Biotechnologies, today announced that the U.S. FDA has granted fast track designation to BPZE1, a next ...
Posted by Michael Wonder on 28 Dec 2021
Vivoryon Therapeutics receives FDA fast track designation for varoglutamstat in early Alzheimer’s disease
22 December 2021 - 21 – Vivoryon Therapeutics today announced that the U.S. FDA has granted fast track designation for varoglutamstat ...
Posted by Michael Wonder on 27 Dec 2021
Celularity receives fast track designation from U.S. FDA for its NK cell therapy CYNK-001 in development for the treatment of AML
27 December 2021 - Celularity today announced the U.S. FDA has granted fast track designation for its non-genetically modified cryopreserved human ...
Posted by Michael Wonder on 26 Dec 2021
Lion TCR receives FDA fast track designation for its HBV specific TCR T cell therapy for hepatocellular carcinoma
23 December 2021 - Lion TCR today announced that it has received fast track designation from U.S. FDA for LioCyx-M004, autologous ...
Posted by Michael Wonder on 26 Dec 2021
Investigational Alzheimer’s disease therapy lecanemab granted FDA fast track designation
23 December 2021 - Eisai and Biogen announced today that lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of ...
Posted by Michael Wonder on 19 Dec 2021
Xalud Therapeutics receives FDA fast track designation for XT-150 for the treatment of pain associated with osteoarthritis of the knee
17 December 2021 - Xalud Therapeutics announced today that the United States FDA has granted fast track designation to the Company’s ...
Posted by Michael Wonder on 15 Dec 2021
Sapience Therapeutics receives FDA fast track designation for ST101 for advanced cutaneous melanoma
15 December 2021 - Sapience Therapeutics announced today that the U.S. FDA has granted fast track designation to its lead program, ...
Posted by Michael Wonder on 15 Dec 2021
Nuvation Bio receives FDA fast track designation for NUV-422 for the treatment of high grade gliomas, including glioblastoma multiforme
15 December 2021 - Nuvation Bio today announced that the U.S. FDA has granted fast track designation to NUV-422, a cyclin-dependent ...
Posted by Michael Wonder on 06 Dec 2021
Sapience Therapeutics receives FDA fast track designation for ST101 for the treatment of recurrent glioblastoma multiforme
6 December 2021 - Sapience Therapeutics announced today that the U.S. FDA has granted fast track designation to its lead ...
Posted by Michael Wonder on 01 Dec 2021
U.S. FDA grants Bionomics fast track designation to BNC210 for the acute treatment of social anxiety disorder and other anxiety related disorders
1 December 2021 - Bionomics is pleased to announce that the U.S. FDA has granted fast track designation to the ...
Posted by Michael Wonder on 30 Nov 2021
Hepion Pharmaceuticals receives FDA fast track designation for CRV431 for the treatment of NASH
30 November 2021 - Hepion Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for the Company’s lead ...
Posted by Michael Wonder on 23 Nov 2021
Isofol Medical receives FDA fast track designation for arfolitixorin in advanced colorectal cancer
23 November 2021 - Isofol Medical announced today that the U.S. FDA has granted fast track designation for the development ...